Findings of a study investigating the stool microbiome of patients with metastatic renal-cell carcinoma (mRCC) receiving vascular-endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs) reveal profound alterations in the microbiota of patients with VEGF-TKI-induced diarrhoea. Patients with diarrhoea had higher levels of Bacteroides spp and lower levels of Prevotella spp than those receiving VEGF-TKIs who did not have diarrhoea. These findings highlight that alterations in faecal microbiota might explain the VEGF-TKI-induced diarrhoea experienced by some, but not all patients receiving this treatment.
References
Pal, S. K. et al. Stool bacteriomic profiling in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor-tyrosine kinase inhibitors. Clin. Cancer Res. 10.1158/1078-0432.CCR-15-0724
Rights and permissions
About this article
Cite this article
Stool microbiome changes in VEGF-TKI-induced diarrhoea. Nat Rev Urol 12, 475 (2015). https://doi.org/10.1038/nrurol.2015.188
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.188